You just read:

Eisai Bewildered as German Institute for Quality and Efficiency in Health Care (IQWIG) Fails to Recognise Additional Benefit of Halaven® (eribulin) in the Treatment of Advanced Liposarcoma

News provided by

Eisai

04 Sep, 2016, 23:01 BST